BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11446316)

  • 1. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
    Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
    Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionation in glioblastoma multiforme.
    Hulshof MC; Schimmel EC; Andries Bosch D; González González D
    Radiother Oncol; 2000 Feb; 54(2):143-8. PubMed ID: 10699477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary glioblastoma multiforme in younger patients: a single-institution experience.
    Ulutin C; Fayda M; Aksu G; Cetinayak O; Kuzhan O; Ors F; Beyzadeoglu M
    Tumori; 2006; 92(5):407-11. PubMed ID: 17168433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme.
    Lutterbach J; Weigel P; Guttenberger R; Hinkelbein W
    Radiother Oncol; 1999 Oct; 53(1):49-52. PubMed ID: 10624853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
    Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
    Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
    Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
    Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
    Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
    Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas.
    Baumert BG; Lutterbach J; Bernays R; Davis JB; Heppner FL
    Radiother Oncol; 2003 May; 67(2):183-90. PubMed ID: 12812849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome.
    Shrieve DC; Alexander E; Black PM; Wen PY; Fine HA; Kooy HM; Loeffler JS
    J Neurosurg; 1999 Jan; 90(1):72-7. PubMed ID: 10413158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
    Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
    Tselis N; Kolotas C; Birn G; Röddiger S; Filipowicz I; Kontova M; Fountzilas G; Selviaridis P; Baltas D; Heyd R; Anagnostopoulos G; Zamboglou N
    Strahlenther Onkol; 2007 Oct; 183(10):563-70. PubMed ID: 17896088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
    Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.
    Nwokedi EC; DiBiase SJ; Jabbour S; Herman J; Amin P; Chin LS
    Neurosurgery; 2002 Jan; 50(1):41-6; discussion 46-7. PubMed ID: 11844233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors.
    Slotman BJ; Kralendonk JH; van Alphen HA; Kamphorst W; Karim AB
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):895-8. PubMed ID: 8598367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.